Evidence map›Paper›PMID 39982479›Full record

ReviewZeitschrift fur Rheumatologie2025

[Rare osteological diseases in the rheumatological consultation: hypophosphatasia and phosphate loss syndromes].

Claus-Jürgen Bauer, Valentin S Schäfer, Zhivana Boyadzhieva, Burkhard Muche

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Claus-Jürgen BauerSektion für Rheumatologie der Medizinischen Klinik III, Universitätsklinikum Bonn, Bonn, Deutschland.
Valentin S SchäferSektion für Rheumatologie der Medizinischen Klinik III, Universitätsklinikum Bonn, Bonn, Deutschland.
Zhivana BoyadzhievaMed. Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie und Interdisziplinäres Zentrum für Osteologie der Charité, Charité Universitätsmedizin Berlin (Campus Mitte), Berlin, Deutschland.
Burkhard MucheMed. Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie und Interdisziplinäres Zentrum für Osteologie der Charité, Charité Universitätsmedizin Berlin (Campus Mitte), Berlin, Deutschland. burkhard.muche@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic bone diseases cause bone and joint pain and are manifested as rheumatism. Typical for the rare genetic disease hypophosphatasia is a reduced activity of alkaline phosphatase (AP), where the variable residual activity causes the heterogeneous symptoms (e.g., arthralgia, myalgia and fractures). It is indicated by repeatedly low AP measurements. The diagnosis requires a meticulous medical history and laboratory-based clarification in order to rule out other differential diagnoses. Although supportive measures form the basis of treatment, costly enzyme replacement therapy is a possible treatment option for severe forms. Multidisciplinary care under the direction of a rheumatologist experienced in osteology or an osteologist is crucial in order to provide adequate care to affected patients. Phosphate loss syndromes due to overactivity of fibroblast growth factor 23 (FGF-23) lead to deformities of the lower extremities and short stature (in congenital disorders), bone and muscle pain, muscular weakness and pathological fractures, depending on the time of occurrence during life. In genetic forms of the disease (especially X‑linked hypophosphatemia), supplementation with calcitriol and phosphates and, if necessary, complex corrective surgery in adolescence are traditional treatment methods, which are increasingly being replaced by treatment with antibodies against FGF-23. The acquired variant is a paraneoplastic phenomenon from small mostly benign mesenchymal tumors, which clinically shows a relatively acute course with severe bone pain, pathological fractures and muscle weakness in previously healthy patients and can ideally be cured by resection of the tumor. The disease can be suspected by significantly reduced serum phosphate levels and narrowed down with further laboratory diagnostics. In our opinion, the measurement of calcium, phosphate and alkaline phosphatase should be part of the primary laboratory diagnostics performed by rheumatologists and the follow-up of pathological findings is indicated.

Indexed as

HypophosphatasiaPhosphatesRare DiseasesRheumatic DiseasesDiagnosis, DifferentialFibroblast Growth Factor-23HumansReferral and ConsultationFGF23 protein, humanFibroblast Growth Factor-23PhosphatesBone painJoint painLaboratory diagnosticsMetabolic bone diseasesMusculoskeletal complaints

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.